There are no known unethical practices during the recent pandemic, however, this lingering mistrust can lead to delayed presentation in the setting of stroke and render Black patients to be ineligible for receiving intravenous tissue plasminogen activator (IV-tPA) treatment [7]. This evidence concerns the gene PLAT and Stroke.